253 related articles for article (PubMed ID: 21752536)
1. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
2. PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.
Cho HJ; Baek KE; Nam IK; Park SM; Kim IK; Park SH; Im MJ; Ryu KJ; Yoo JM; Hong SC; Kim JW; Lee CW; Yoo J
Biochem Biophys Res Commun; 2011 Oct; 414(3):575-80. PubMed ID: 21986528
[TBL] [Abstract][Full Text] [Related]
3. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
4. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
5. Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer.
Cho HJ; Baek KE; Kim IK; Park SM; Choi YL; Nam IK; Park SH; Im MJ; Yoo JM; Ryu KJ; Oh YT; Hong SC; Kwon OH; Kim JW; Lee CW; Yoo J
J Proteome Res; 2012 Apr; 11(4):2355-64. PubMed ID: 22364609
[TBL] [Abstract][Full Text] [Related]
6. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
Wu Y; McRoberts K; Berr SS; Frierson HF; Conaway M; Theodorescu D
Oncogene; 2007 Feb; 26(5):765-73. PubMed ID: 16878152
[TBL] [Abstract][Full Text] [Related]
7. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis.
Zhang B; Zhang Y; Dagher MC; Shacter E
Cancer Res; 2005 Jul; 65(14):6054-62. PubMed ID: 16024605
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.
Kim IK; Park SM; Cho HJ; Baek KE; Nam IK; Park SH; Ryu KJ; Ryu J; Choi J; Hong SC; Kim JW; Lee CW; Kang SS; Yoo J
Oncotarget; 2013 Nov; 4(11):2045-56. PubMed ID: 24185104
[TBL] [Abstract][Full Text] [Related]
9. RhoGDI2 as a therapeutic target in cancer.
Cho HJ; Baek KE; Yoo J
Expert Opin Ther Targets; 2010 Jan; 14(1):67-75. PubMed ID: 20001211
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 (CPP32) in bax-transfected gastric cancer cells.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 2000; 20(1A):439-44. PubMed ID: 10769693
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells.
Zhang LJ; Hao YZ; Hu CS; Ye Y; Xie QP; Thorne RF; Hersey P; Zhang XD
Anticancer Drugs; 2008 Feb; 19(2):159-66. PubMed ID: 18176112
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination.
Chanvorachote P; Nimmannit U; Stehlik C; Wang L; Jiang BH; Ongpipatanakul B; Rojanasakul Y
Cancer Res; 2006 Jun; 66(12):6353-60. PubMed ID: 16778213
[TBL] [Abstract][Full Text] [Related]
14. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
Cho HJ; Kim JK; Kim KD; Yoon HK; Cho MY; Park YP; Jeon JH; Lee ES; Byun SS; Lim HM; Song EY; Lim JS; Yoon DY; Lee HG; Choe YK
Cancer Lett; 2006 Jun; 237(1):56-66. PubMed ID: 16009487
[TBL] [Abstract][Full Text] [Related]
16. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells.
Kondo S; Shinomura Y; Kanayama S; Higashimoto Y; Kiyohara T; Zushi S; Kitamura S; Ueyama H; Matsuzawa Y
Oncogene; 1998 Nov; 17(20):2585-91. PubMed ID: 9840921
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA.
Hao JH; Gu QL; Liu BY; Li JF; Chen XH; Ji YB; Zhu ZG; Lin YZ
Chin Med J (Engl); 2007 Dec; 120(23):2105-11. PubMed ID: 18167184
[TBL] [Abstract][Full Text] [Related]
19. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis.
Jiang M; Wei Q; Wang J; Du Q; Yu J; Zhang L; Dong Z
Oncogene; 2006 Jul; 25(29):4056-66. PubMed ID: 16491117
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation.
Kutuk O; Arisan ED; Tezil T; Shoshan MC; Basaga H
Carcinogenesis; 2009 Sep; 30(9):1517-27. PubMed ID: 19578044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
